A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

BackgroundProlgolimab is the first Russian PD-1 inhibitor approved for the first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was approved in two weight-based regimens of 1 mg/kg Q2W and 3 mg/kg Q3W, but because of re-evaluation of weight-based do...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Lev Demidov, Galina Kharkevich, Natalia Petenko, Vladimir Moiseenko, Svetlana Protsenko, Tatiana Semiglazova, Anastasia Zimina, Nadezhda Kovalenko, Natalia Fadeeva, Dmitry Kirtbaya, Igor Belogortsev, Denis Tantsyrev, Svetlana Odintsova, Alfia Nesterova, Karina Vorontsova, Yulia Makarycheva, Yulia Linkova, Arina Zinkina-Orikhan, Anna Siliutina, Irina Sorokina, Daria Liaptseva, Vladimir Chistyakov, Anton Lutsky
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Frontiers Media S.A. 2024-09-01
Cyfres:	Frontiers in Oncology
Pynciau:	melanoma PD-1 inhibitor fixed dose prolgolimab immunotherapy
Mynediad Ar-lein:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1385685/full
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!